Skip to main content
. 2021 Nov 3;1(5):451–457. doi: 10.21873/cdp.10060

Table III. Treatment outcomes and adverse events.

graphic file with name cdp-1-453-i0002.jpg

DEC: Docetaxel; estramustine and carboplatin; IQR: interquartile range; P-PFS: prostate-specific antigen progression-free survival; PSA: prostate-specific antigen; R-PSF: radiographic progression-free survival.